Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Amyloid. 2009;16(3):183-5. doi: 10.1080/13506120903090924.
A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of amyloidogenic immunoglobulin light chains.
一位患有原发性 AL 淀粉样变性的男性患者，曾患有全身淋巴结病伴 IgMkappa 型 M 蛋白血症，接受了两周期 VAD 和大剂量马法兰治疗，并使用利妥昔单抗清除 CD20(+)细胞，随后进行了自体外周血干细胞移植。完全血液学缓解后 4 年，淀粉样蛋白负荷的淋巴结明显缩小。如果化疗能持续抑制淀粉样蛋白轻链的产生，使 AL 淀粉样物质在组织中得到消退。
